Survey

ADVANCED MANAGEMENT STRATEGIES FOR ALZHEIMER'S DISEASE

Now that you have completed this educational activity, please help us assess its effectiveness. Please note: THIS IS NOT THE POST TEST.

Please indicate your profession:

Please indicate your profession: Clinical Pharmacist

Consultant Pharmacist

Retail Pharmacist

Staff Pharmacist

VA Pharmacist

Other (please specify)

Please rate your level of agreement with the following:

	Strongly Agree 6	5	4	3	2	Strongly Disagree 1
If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued.	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. Strongly Agree 6	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. 5	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. 4	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. 3	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. 2	If combined pharmacotherapy with a cholinesterase inhibitor (ChEI) plus an N-methyl-D-aspartic acid (NMDA) receptor antagonist appears to have no tangible beneficial effects, they should both be discontinued. Strongly Disagree 1
Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon.	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. Strongly Agree 6	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. 5	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. 4	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. 3	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. 2	Current Alzheimer's disease research shows that promising disease-modifying therapies are on the horizon. Strongly Disagree 1
In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia.	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. Strongly Agree 6	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. 5	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. 4	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. 3	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. 2	In my facility, management of agitation and aggression is the biggest challenge in patients with severe dementia. Strongly Disagree 1

Please choose the most appropriate answer:

Which of the following medications is most often associated with nightmares and vivid dreams?

Please choose the most appropriate answer:

Which of the following medications is most often associated with nightmares and vivid dreams? Donepezil

Galantamine

Rivastigmine

Memantine

Please indicate how you would manage the following scenario:

Mrs. S. is a 72-year old woman with moderate dementia. She has been on a ChEI and NMDA-receptor antagonist for 6 months. Family has not noted any improvement and her dementia is stable. She has not exhibited any signs of adverse effects from the medications. How would you counsel the family members about her current treatment?

Please indicate how you would manage the following scenario:

Mrs. S. is a 72-year old woman with moderate dementia. She has been on a ChEI and NMDA-receptor antagonist for 6 months. Family has not noted any improvement and her dementia is stable. She has not exhibited any signs of adverse effects from the medications. How would you counsel the family members about her current treatment? Discontinue her medications for AD because her dementia is stable

Do not discontinue her medications because they may be slowing the progression of her dementia

Reduce the dosages of her medications to see if there is a change in status

Increase the dosages to improve her symptoms

Thank you for completing the survey. Once you click "done" your results will be submitted and you will be taken to the post-test and evaluation.

Please indicate your profession:

Please choose the most appropriate answer: Which of the following medications is most often associated with nightmares and vivid dreams?

Please choose the most appropriate answer:

Which of the following medications is most often associated with nightmares and vivid dreams?